FMP
Aurinia Pharmaceuticals Inc.
AUP.TO
TSX
Inactive Equity
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. The company is headquartered in Victoria, Canada.
16.76 CAD
-0.6100006 (-3.64%)
About
ceo
Mr. Peter Greenleaf
sector
Healthcare
industry
Medical - Specialties
website
http://www.auriniapharma.com
exchange
TSX
Description
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. The company is headquartered in Victoria, Canada.
CIK
N/A
ISIN
N/A
CUSIP
N/A
Address
1203-4464 Markham St
Phone
12507084272
Country
CA
Employee
294
IPO Date
Sep 19, 2000
Key Executives
